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Replication-deficient adenoviruses (rec-AdV) expressing
different transgenes are widely employed vectors for gene
therapy and vaccination. We examined here the genera-
tion of β-galactosidase (βgal)-specific CTL following
administration of βgal-recombinant adenovirus (Ad-
LacZ). Using MHC class I tetramers to track βgal-specific
CTL in different organs, we found that a significant expan-
sion of βgal-specific CTL could only be achieved in a very
narrow dose range (2 × 108 – 2 × 109 pfu). Functional
analysis revealed that adenovirus-induced βgal-specific
CTL produced only very low amounts of effector cytokines
and were unable to lyse βgal peptide-pulsed target cells.
Injection of optimal doses of Ad-LacZ into transgenic
mice which express βgal exclusively in non-lymphoid
organs, led to physical deletion of βgal-specific CTL. Our
results indicate first that CTL deletion in the course of ade-
noviral vaccination is preceded by their functional impair-
ment and second, that the outcome of rec-AdV
vaccination depends critically on the antigen load in
peripheral tissues. The presented findings thus impinge
on the rationale to use adenoviral vectors in clinical vacci-
nation.
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